Literature DB >> 34224270

The single-dose J&J vaccine had 67% efficacy against moderate to severe-critical COVID-19 at ≥14 d.

Henry S Sacks1.   

Abstract

SOURCE CITATION: Sadoff J, Gray G, Vandebosch A, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021. [Epub ahead of print.] 33882225.

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34224270     DOI： 10.7326/ACPJ202107200-075

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   25.391


  4 in total

Review 1.  [Overview of COVID-19 vaccines licensed in the EU-from technology via clinical trial to registration].

Authors:  Eberhard Hildt
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2022-10-18       Impact factor: 1.595

Review 2.  Anti-inflammatory and anti-viral actions of anionic pulmonary surfactant phospholipids.

Authors:  Mari Numata; Dennis R Voelker
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2022-02-28       Impact factor: 5.228

Review 3.  COVID-19 vaccination challenges: A mini-review.

Authors:  Zeinab Mohseni Afshar; Mohammad Barary; Rezvan Hosseinzadeh; Bardia Karim; Soheil Ebrahimpour; Kosar Nazary; Terence T Sio; Mark J M Sullman; Kristin Carson-Chahhoud; Emaduddin Moudi; Arefeh Babazadeh
Journal:  Hum Vaccin Immunother       Date:  2022-05-05       Impact factor: 4.526

4.  Changes Over Time in COVID-19 Incidence, Vaccinations, Serum Spike IgG, and Viral Neutralizing Potential Among Individuals From a North American Gaming Venue: December 2020-August 2021.

Authors:  Adam V Wisnewski; Linda Cantley; Julian Campillo Luna; Jian Liu; Richard F Smith; Kelly Hager; Carrie A Redlich
Journal:  J Occup Environ Med       Date:  2022-07-07       Impact factor: 2.306
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.